دورية أكاديمية
أعرض في EDS

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.

التفاصيل البيبلوغرافية
العنوان: Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
المؤلفون: Carles J; Department of Medical Oncology, Hospital del Mar-URTEC, Barcelona, Spain. jcarles@imas.imim.es, Font A, Mellado B, Domenech M, Gallardo E, González-Larriba JL, Catalan G, Alfaro J, Gonzalez Del Alba A, Nogué M, Lianes P, Tello JM
المصدر: British journal of cancer [Br J Cancer] 2007 Nov 05; Vol. 97 (9), pp. 1206-10. Date of Electronic Publication: 2007 Oct 23.
نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0007-0920 (Print) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.
مواضيع طبية MeSH: Adenocarcinoma/*drug therapy , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Neoplasms, Hormone-Dependent/*drug therapy , Prostatic Neoplasms/*drug therapy, Adenocarcinoma/pathology ; Aged ; Bone Neoplasms/drug therapy ; Bone Neoplasms/secondary ; Celecoxib ; Disease Progression ; Docetaxel ; Drug Administration Schedule ; Estramustine/administration & dosage ; Humans ; Male ; Middle Aged ; Neoplasms, Hormone-Dependent/pathology ; Prospective Studies ; Prostatic Neoplasms/pathology ; Pyrazoles/administration & dosage ; Soft Tissue Neoplasms/drug therapy ; Soft Tissue Neoplasms/secondary ; Sulfonamides/administration & dosage ; Survival Rate ; Taxoids/administration & dosage
مستخلص: The objective of this study was to evaluate the efficacy and safety profile of weekly docetaxel, estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer. Forty-eight patients received 35 mg m(-2) of weekly docetaxel for 3 out of every 4 weeks, 280 mg of estramustine twice daily on days 1-3, 8-10, 15-17 and 400 mg of celecoxib twice daily until progression or toxicity. Cycles were repeated every 28 days for at least six cycles. Patients were evaluated for response and toxicity. Patients received a median of four cycles (range: 1-9). On an intention-to-treat analysis, prostate-specific antigen (PSA) was decreased greater than 50% in 28 out of 48 patients (overall response rate: 58%, 95% confidence interval (CI): 44-72) and median duration of PSA response was 8.0 months (95% CI: 6.9-9.0). After a median follow-up of 11.3 months, the median time to progression was 7.1 months and the median overall survival was 19.2 months. The most frequent severe toxicity was asthenia (15% of patients), diarrhoea and stomatitis (8% of patients, each). Grade 3/4 neutropenia was reported in two patients. There was a toxic death during the study due to a gastric perforation. Celecoxib with weekly docetaxel and estramustine is an effective and safe treatment for patients with hormone-refractory prostate cancer, but it does not seem to add any benefit to docetaxel.
References: J Urol. 2002 Dec;168(6):2439-43. (PMID: 12441935)
J Coll Physicians Surg Pak. 2003 Jun;13(6):361-5. (PMID: 12814542)
J Clin Oncol. 2006 Jun 20;24(18):2723-8. (PMID: 16782912)
N Engl J Med. 2004 Oct 7;351(15):1513-20. (PMID: 15470214)
J Urol. 2000 Sep;164(3 Pt 1):820-5. (PMID: 10953162)
J Clin Oncol. 1999 Nov;17(11):3461-7. (PMID: 10550143)
J Clin Oncol. 1998 Jun;16(6):2164-8. (PMID: 9626217)
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. (PMID: 10655437)
J Clin Oncol. 2005 May 20;23(15):3343-51. (PMID: 15738542)
Lancet Oncol. 2003 Oct;4(10):605-15. (PMID: 14554238)
Anesthesiology. 1999 Nov;91(5):1548-9. (PMID: 10551614)
Semin Oncol. 2001 Aug;28(4 Suppl 15):16-21. (PMID: 11685724)
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7. (PMID: 16609031)
N Engl J Med. 1989 Aug 17;321(7):419-24. (PMID: 2503724)
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005247. (PMID: 17054249)
N Engl J Med. 2004 Oct 7;351(15):1502-12. (PMID: 15470213)
JAMA. 1999 May 5;281(17):1591-7. (PMID: 10235151)
Cancer. 1993 Feb 1;71(3 Suppl):1098-109. (PMID: 7679039)
J Clin Oncol. 2001 May 1;19(9):2509-16. (PMID: 11331330)
J Clin Oncol. 1996 Jun;14(6):1756-64. (PMID: 8656243)
Prostate. 2000 Jan;42(1):73-8. (PMID: 10579801)
المشرفين على المادة: 0 (Pyrazoles)
0 (Sulfonamides)
0 (Taxoids)
15H5577CQD (Docetaxel)
35LT29625A (Estramustine)
JCX84Q7J1L (Celecoxib)
تواريخ الأحداث: Date Created: 20071024 Date Completed: 20071219 Latest Revision: 20220216
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC2360463
DOI: 10.1038/sj.bjc.6604030
PMID: 17955053
قاعدة البيانات: MEDLINE
الوصف
تدمد:0007-0920
DOI:10.1038/sj.bjc.6604030